EyePoint’s Phase 3 wet‑AMD trial misses primary endpoint, prompting 53% workforce cut
EyePoint announced that its Phase 3 LUCIA study of DURAVYU in wet age‑related macular degeneration failed to meet the primary non‑inferiority endpoint. The company will discontinue the wet‑AMD program early, cut roughly 53% of its staff, and redirect resources to its diabetic macular edema (DME) program, with Phase 3 DME readouts expected in Q4 2027.
Why it matters
The restructuring is projected to generate about $30 million of annualized cost savings and preserve the company’s $118 million cash balance through 2027. Analysts note the trial miss has triggered a sharp share decline and a downgrade, reflecting heightened execution risk.
Key facts
- 1The LUCIA Phase 3 trial of DURAVYU did not achieve its primary endpoint of non‑inferiority in wet AMD. finance.yahoo.com
- 2EyePoint will eliminate approximately 53% of its workforce. finance.yahoo.com
- 3The restructuring is expected to save roughly $30 million annually. finance.yahoo.com
- 4One‑time employee‑related charges are estimated at about $9 million. finance.yahoo.com
- 5EyePoint reported cash, cash equivalents and short‑term investments of approximately $118 million as of 30 September 2026. finance.yahoo.com
- 6Phase 3 DME trials (COMO and CAPRI) are slated to deliver topline results in the fourth quarter of 2027. finance.yahoo.com
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.